Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074083 | 0.94 | SMN1; SMN2 (0.52) | HTTKMT2AP2RX7ALDH1A1HPGD | |
| SCHEMBL4246819 | 0.85 | P2RX7 (0.54) | HTTKMT2AP2RX7ALDH1A1MEN1 | |
| SCHEMBL7934893 | 0.83 | P2RX7 (0.53) | KMT2AP2RX7ALDH1A1MEN1ERCC1 | |
| SCHEMBL4074090 | 0.82 | P2RX7 (0.40) | HTTKMT2AP2RX7ALDH1A1HPGD | |
| SCHEMBL3557506 | 0.81 | P2RX7 (0.53) | KMT2AP2RX7ALDH1A1TP53MEN1 | |
| SCHEMBL11867707 | 0.80 | ALDH1A1 (0.58) | HTTKMT2AP2RX7ALDH1A1TP53 | |
| SCHEMBL5797584 | 0.79 | P2RX7 (0.49) | KMT2AP2RX7ALDH1A1MEN1ERCC1 | |
| SCHEMBL626586 | 0.79 | CYP2C9 (0.58) | KMT2AP2RX7ALDH1A1MEN1ERCC1 | |
| SCHEMBL6649593 | 0.78 | HTT (0.69) | HTTKMT2AP2RX7ALDH1A1HPGD | |
| SCHEMBL18887625 | 0.77 | LMNA (0.50) | HTTKMT2AP2RX7ALDH1A1ERCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| EP-1745010-B1 | SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | HTT 422/4885KMT2A 3604/4885P2RX7 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.